Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Disulfiram Overcomes Cisplatin Resistance in Human Embryonal Carcinoma Cells.

Schmidtova S, Kalavska K, Gercakova K, Cierna Z, Miklikova S, Smolkova B, Buocikova V, Miskovska V, Durinikova E, Burikova M, Chovanec M, Matuskova M, Mego M, Kucerova L.

Cancers (Basel). 2019 Aug 22;11(9). pii: E1224. doi: 10.3390/cancers11091224.

2.

Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer.

Lazzari L, Corti G, Picco G, Isella C, Montone M, Arcella P, Durinikova E, Zanella ER, Novara L, Barbosa F, Cassingena A, Cancelliere C, Medico E, Sartore-Bianchi A, Siena S, Garnett MJ, Bertotti A, Trusolino L, Di Nicolantonio F, Linnebacher M, Bardelli A, Arena S.

Clin Cancer Res. 2019 Aug 2. doi: 10.1158/1078-0432.CCR-18-3440. [Epub ahead of print]

PMID:
31375513
3.

Type 3 inositol 1,4,5-trisphosphate receptor has antiapoptotic and proliferative role in cancer cells.

Rezuchova I, Hudecova S, Soltysova A, Matuskova M, Durinikova E, Chovancova B, Zuzcak M, Cihova M, Burikova M, Penesova A, Lencesova L, Breza J, Krizanova O.

Cell Death Dis. 2019 Feb 22;10(3):186. doi: 10.1038/s41419-019-1433-4.

4.

ALDH1A3 upregulation and spontaneous metastasis formation is associated with acquired chemoresistance in colorectal cancer cells.

Durinikova E, Kozovska Z, Poturnajova M, Plava J, Cierna Z, Babelova A, Bohovic R, Schmidtova S, Tomas M, Kucerova L, Matuskova M.

BMC Cancer. 2018 Aug 24;18(1):848. doi: 10.1186/s12885-018-4758-y.

5.

Cytotoxic response of 5-fluorouracil-resistant cells to gene- and cell-directed enzyme/prodrug treatment.

Durinikova E, Plava J, Tyciakova S, Skvara P, Vojs Stanova A, Kozovska Z, Kucerova L, Matuskova M.

Cancer Gene Ther. 2018 Dec;25(11-12):285-299. doi: 10.1038/s41417-018-0030-5. Epub 2018 Jun 21.

PMID:
29925898
6.

ALDH1A inhibition sensitizes colon cancer cells to chemotherapy.

Kozovska Z, Patsalias A, Bajzik V, Durinikova E, Demkova L, Jargasova S, Smolkova B, Plava J, Kucerova L, Matuskova M.

BMC Cancer. 2018 Jun 15;18(1):656. doi: 10.1186/s12885-018-4572-6.

7.

Genetically engineered mesenchymal stromal cells in cancer gene therapy.

Matuskova M, Durinikova E, Altaner C, Kucerova L.

Bratisl Lek Listy. 2018;119(4):221-223. doi: 10.4149/BLL_2018_041. Review.

PMID:
29663820
8.

Targeted antitumor therapy mediated by prodrug-activating mesenchymal stromal cells.

Kucerova L, Durinikova E, Toro L, Cihova M, Miklikova S, Poturnajova M, Kozovska Z, Matuskova M.

Cancer Lett. 2017 Nov 1;408:1-9. doi: 10.1016/j.canlet.2017.08.016. Epub 2017 Aug 25. Review.

PMID:
28838843
9.

Erratum to: Cisplatin-induced mesenchymal stromal cells-mediated mechanism contributing to decreased antitumor effect in breast cancer cells.

Skolekova S, Matuskova M, Bohac M, Toro L, Durinikova E, Tyciakova S, Demkova L, Gursky J, Kucerova L.

Cell Commun Signal. 2016 Feb 25;14:7. doi: 10.1186/s12964-016-0130-5. No abstract available.

10.

Cisplatin-induced mesenchymal stromal cells-mediated mechanism contributing to decreased antitumor effect in breast cancer cells.

Skolekova S, Matuskova M, Bohac M, Toro L, Durinikova E, Tyciakova S, Demkova L, Gursky J, Kucerova L.

Cell Commun Signal. 2016 Jan 12;14:4. doi: 10.1186/s12964-016-0127-0. Erratum in: Cell Commun Signal. 2016;14:7. Durinikova, Erika [added]; Tyciakova, Silvia [added].

11.

3D multicellular models reflect the efficiency of MSC-directed enzyme/prodrug treatment.

Bohovic R, Demkova L, Cihova M, Skolekova S, Durinikova E, Toro L, Tyciakova S, Kozovska Z, Matuskova M, Kucerova L.

Neoplasma. 2015;62(4):521-30. doi: 10.4149/neo_2015_063.

PMID:
25997965
12.

Combined enzyme/prodrug treatment by genetically engineered AT-MSC exerts synergy and inhibits growth of MDA-MB-231 induced lung metastases.

Matuskova M, Kozovska Z, Toro L, Durinikova E, Tyciakova S, Cierna Z, Bohovic R, Kucerova L.

J Exp Clin Cancer Res. 2015 Apr 9;34:33. doi: 10.1186/s13046-015-0149-2.

13.

Mesenchymal stromal cells retrovirally transduced with prodrug-converting genes are suitable vehicles for cancer gene therapy.

Ďuriniková E, Kučerová L, Matúšková M.

Acta Virol. 2014;58(1):1-13. Review.

PMID:
24717023
14.

Intrinsic properties of tumour cells have a key impact on the bystander effect mediated by genetically engineered mesenchymal stromal cells.

Matuskova M, Baranovicova L, Kozovska Z, Durinikova E, Pastorakova A, Hunakova L, Waczulikova I, Nencka R, Kucerova L.

J Gene Med. 2012 Dec;14(12):776-87. doi: 10.1002/jgm.2684.

PMID:
23150190

Supplemental Content

Loading ...
Support Center